Back to search results

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Radiotherapy and Immunotherapy

This observational study is looking at how combined thoracic radiotherapy (radiation to the chest) and immunotherapy (drugs that boost your body's immune system) affect the heart and lungs of people with lung cancer. Researchers want to understand any heart or lung side effects that might happen. You could join if you are over 18, have locally advanced lung cancer (non-small cell lung cancer or small cell lung cancer), and are planning to receive curative radiotherapy (45 Gy or higher) and immunotherapy. The study aims to identify potential markers in the body that could predict these side effects. The current status of this study is unclear.

Study design
This is an observational study that plans to enroll 125 participants. It is not a randomized study, meaning participants will not be assigned to different treatment groups.
What's involved
The study involves timed monitoring and blood sample collection. These will occur for up to 25 months after thoracic radiotherapy and 12 months after immunotherapy.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for clinical cardiopulmonary toxicities for up to 25 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06410300

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Recruiting
Not specifiedAges 18+Observational
Bo Lu
~125 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:Curative RadiotherapyImmunotherapy

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical cardiopulmonary toxicities
Measured over 25 months

Conditions

Lung Cancer

Explore related trials

Lung Non-Small Cell CarcinomaLung Small Cell Carcinoma

Where it's being run

3 sites across 3 states
Missouri1
New Jersey1
New York1

Study leadership

  • Bo Lu, MD · PRINCIPAL_INVESTIGATOR · Chair, Department of Radiation Oncology

Who to contact

Brooke McDaniel
[email protected]
(573) 882-7440
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient older than 18 years age
Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.
Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
ECOG performance status of 0-2
Life expectancy of 6 months or longer
Patient able to provide a written informed consent prior to study entry

Exclusion

Prior thoracic radiotherapy to chest.
Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

What this trial measures

  • Clinical cardiopulmonary toxicities25 months

    To determine clinical cardiopulmonary toxicities from standard RT and immunotherapy per CTCAEv5.0